awmsg logo



levodopa-carbidopa intestinal gel (Duodopa®)


Reference No. 3397


Appraisal information

levodopa-carbidopa intestinal gel (Duodopa®) 20 mg/ml + 5 mg/ml intestinal gel


Company: AbbVie Ltd
BNF category: Central nervous system
NMG meeting date: 04/10/2017
AWMSG meeting date: 08/11/2017
   
   
Submission Type: Resubmission
Status: Suspended
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results